We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are ...

Regeneron Pharmaceuticals ... The other promising drug is in their growing oncology pipeline, as Zaltrap has given way to Libtayo, their treatment for metastatic melanoma. Libtayo was originally ...

Allow some time for an explanation There are two ways of looking at Regeneron. The sum-of-the-parts way and the platform way.

Regeneron is to collaborate with Inovio to investigate a three-way immunotherapy combination against glioblastoma multiforme (GBM), an aggressive and hard-to-treat brain tumour. Regeneron’s drug ...

TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent for the treatment of chronic ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Regeneron’s (REGN) treatment of lipodystrophy, mibavademab, was granted FDA orphan designation, according to a post on the agency’s website. See what stocks are receiving Strong Buy ratings ...

Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Allow some time for an explanation There are two ways of looking at Regeneron. The sum-of-the-parts way and the platform way.